TITLE OF PROJECT

Biological Effects of Radiation, Metabolic and Replication Kinetics Alterations.

Principal Investigator:
Joseph Post, M.D.
Professor of Clinical Medicine
New York University - Research Service
Goldwater Memorial Hospital
Roosevelt Island, New York, N.Y. 10017

FINAL PROGRESS REPORT
31 January 1972 - 31 December 1972

NASA Contract No. NGR 33-016-102
INTRODUCTION

During the life of this contract studies have been designed and carried out examining in vivo and in vitro the biological effects of radiation upon normal and cancerous tissues. Tritium ($^3$H), usually in the form of tritiated thymidine ($^3$HTdR), has been employed exclusively in these experiments. A macromolecular precursor of DNA, $^3$HTdR is incorporated into the cell nucleus during synthesis and provides intranuclear beta radiation. Tritium-labeled cells were studied with autoradiographic methods; cell cycle kinetics were determined and cell function modified by radiation dosage or by drugs was also evaluated. The long term program has included: 1) the effects of radiation on cell replication and the correlation with incorporated dose levels, 2) radiation-induced changes in cell function, viz., the response of beta-irradiated spleen lymphocytes to antigenic stimulation by sheep red blood cells (SRBC), 3) the kinetics of tumor and normal cell replication and 4) megakaryocyte formation and modification by radiomimetic drugs. The results of some of these studies, having been published or described in previous annual reports, will only be summarized, and the others will be detailed.

I. Effects of Radiation on Cell Replication; Correlation with Incorporated Dose Levels.

Previous investigations have shown that increasing doses of $^3$HTdR will disrupt the mitotic labeling (PIM) curves of rat hepatocytes, spleen lymphocytes or ileal crypt cells in vivo (1-4) and that the effects are dose-dependent. A similar experiment performed in vitro
with HeLa\textsubscript{S3} cells showed that increasing doses of \textsuperscript{3}HTdR as a pulse label produced marked distortions of the PIM curve, which were dose-dependent. These were similar qualitatively to those changes induced in vivo. (Fig. 2-6). These findings eliminate the possibility of \textsuperscript{3}HTdR re-utilization as a factor and establish the changes as effects of beta radiation.

Experiments to determine the amounts of radioactivity incorporated by the nuclei at the different dose levels were continued. Nuclei were isolated by density gradient methods; aliquots of equal volume were then taken for DNA determination, radioactivity assays in a liquid scintillation counter and particle counting in a Coulter counter. Incorporated activity was thus determined in rads per gram of nuclear DNA and then calculated for labeled nuclei from the labeling indices in autoradiographs. The results show that there is a good correlation between the labeling dose and the incorporated radioactivity (Table 1). The hepatocytes, after 1.0 $\mu$Ci/gm absorbed an average radiation dose equivalent to $4.58 \times 10^{-9}$ rads per day per labeled nucleus while the splenic lymphocytes showed an average absorption of $1.17 \times 10^{-9}$ rads per day. The radioactivity in the HeLa\textsubscript{S3} cells rose from $1.44 \times 10^{-10}$ rads after 0.01 $\mu$Ci/ml to $1.49 \times 10^{-7}$ rads after 10 $\mu$Ci/ml.

As mentioned in previous reports the finding that the PIM curves of HeLa\textsubscript{S3} cells were altered by doses of \textsuperscript{3}HTdR as small as 0.1 $\mu$Ci/ml certainly suggests that in metabolic studies where radioactive precursors are employed the sensitivity of the biological specimens to radiation effects must be investigated.
II. Radiation Induced Changes in Cell Function.

The finding that the cycling of rat splenic lymphocytes was still perturbed 5 weeks after a dose of 10 μCi/gm, even after the disappearance of all labeling (4), raised the possibility of alteration of the genome of these lymphocytes. This in turn suggested that these cells might also have undergone changes in functional behaviour. The response of these cells to antigenic stimulation was tested.

As reported last year the labeling index of splenic lymphocytes from rats pre-treated with \(^3\)HTdR, 10 μCi/gm, does not rise as briskly as that of controls following a challenging dose of sheep erythrocytes (SRBC). This has been interpreted as showing that the disturbance of cell kinetics by \(^3\)HTdR dampens the synchronized increase in the number of cells entering DNA synthesis following SRBC.

A more specific index of functional change is the production of blood hemolysin after SRBC. This was studied in both pre-treated and control animals. Male Wistar rats 3 weeks old, were injected I.P. with \(^3\)HTdR, 10 μCi/gm. Five weeks later they received 1 ml of 1% SRBC solution I.V. Blood samples were drawn from the respective animals at intervals of 1 to 10 days and analyzed quantitatively for levels of hemolysis. The same procedure was carried out in control 8 week-old animals who had not received any \(^3\)HTdR. The data show that the control animals exhibit slowly rising titres that never reach above a mean of 1:52 (on day 5), and tend to plateau at very low levels through day 10 (Fig. 7) In the irradiated rats on the other hand, the titre rises on day 3, peaks sharply at 1:300 on day 4, diminishes gradually to a broad trough at 1:72 on days 8 and 9 and then peaks
again on day 10 to over 1:400 (Fig. 8). These results indicate that radiation has altered the response of the spleen lymphocytes. These studies have not been pursued because of lack of support. Thus, radiation-induced altered cell replication may be associated with other metabolic changes.

III. Normal and Tumor Cell Replication

A. Normal Cells

The investigations of the effects of various drugs on cell cycling have been concluded. Studies were done with methotrexate, nitrogen mustard and hydrocortisone and the results were similar to those found with TUDR, namely alteration in the replication cycle with slowing of DNA synthesis, arrest in $G_2$ and reduction in the mitotic index. A reprint is enclosed.

The studies with germfree rats have also been concluded and showed that the mitotic labeling curves of spleen lymphocytes and ileal crypt cells are not altered by the sterile state. A reprint is enclosed.

B. Tumor Cells

Studies of the replication kinetics of tumor cells have continued and the movement of normal and tumor cells between proliferating and non-proliferating compartments has been examined using the methods described in our last report. The model has been the autogenous rat sarcoma produced with 3-methylcholanthrene (3-MC). The results show that only 40-60% of the initial cohort of cells in DNA synthesis (S) complete mitosis and enter $G_1$ to continue cycling.
About 20-35% of the S cohort leaves the cycle and stays in $G_2$ for long periods of time and 20-40% of the residual S cohort spends protracted times in $G_1$. The movement of cells is bidirectional, entering or leaving the cycle from either the proliferating or the non-proliferating compartments. The continual turnover of the compartments is a major determinant of tumor growth. Clinically this becomes a major factor in therapy. If a tumor has a large non-proliferating compartment the administration of cytotoxic agents designed to interfere with cell cycling will of necessity produce disappointing results.

Since the use of antitumor agents in man has been limited by their adverse effects on the coexistent normal replicating tissues such as the gastrointestinal tract or the hematopoietic system, dose levels have been maintained to avoid undue toxicity to the host tissue. It is conceivable therefore that many tumor as well as normal cells may escape the lethal damage of cytotoxins. Since the continued growth of the tumor is thus dependent on these surviving cells it was of interest to examine the proliferation pattern of tumor cells after one of these drugs.

Rats with 3-MC-induced sarcomas received nitrogen mustard ($HN_2$), 0.1 mgm/kg, daily for varying periods up to 7 days. Four groups of experiments were performed and cell proliferation was studied with continuous infusions of $^{3}$HdR (See reprint). Tumor growth stopped during $HN_2$ administration with a fall in mitotic indices, and mitotic and interphase labeling rates. Most mitoses were unlabeled, derived from $G_{20}$ cells. Tumor growth resumed after withdrawal of $HN_2$, the mitotic index and labeling rate returning to pretreatment levels. Interphase labeling lagged behind however, and thus it appeared that the pre-
treatment growth rate was associated with a reduced proliferating pool.

Of further interest to us has been the general observation that most antitumor agents have been tested for their cell-killing abilities or cycle-disrupting affinities in in vitro systems. In order to achieve a therapeutic effect of reasonable value in the host it is implicit in such studies that tumor cell replication in vivo be similar to that found in tissue culture. Accordingly tumor cells were taken from samples of four individual 3-MC induced autogenous rat sarcomas and grown in tissue culture. They were pulse-labeled with $^3$HThdR, 0.1 μCi/ml, PLM curves were derived and the replication kinetics of the tumor cells grown in vitro were determined. The cycle time (Tc) was about 17 hours, S was about 6 hours and G$_1$ was estimated at 6-8 hours (Fig. 9). In the tumor grown in vivo, Tc was 40 hours, S was 24 hours and G$_1$ was about 14 hours (5). The data indicate the obvious differences between cell replication in vitro and in vivo and emphasize the importance of establishing a more effective method for choosing and testing drugs with potential tumoricidal properties.

We wish to thank the National Aeronautics and Space Agency for the continued support that enabled us over the past several years to continue investigations in the field of radiation research.
PUBLICATIONS


# REFERENCES

FIGURE LEGENDS

Fig. 1. Mitotic Labeling Curves - hepatocytes and spleen lymphocytes.
Fig. 2. Mitotic Labeling Curve - HeLaS<sub>3</sub> - 0.01 μCi/ml.
Fig. 3. Mitotic Labeling Curve - HeLaS<sub>3</sub> - 0.1 μCi/ml.
Fig. 4. Mitotic Labeling Curve - HeLaS<sub>3</sub> - 1.0 μCi/ml.
Fig. 5. Mitotic Labeling Curve - HeLaS<sub>3</sub> - 2.0 μCi/ml.
Fig. 6. Mitotic Labeling Curve - HeLaS<sub>3</sub> - 10. μCi/ml.
Fig. 7. Hemolysin Response to SRBC - Non-radiated rats
Fig. 8. Hemolysin Response to SRBC - rats treated with 3HTdR, 10 μCi/gm
Fig. 9. Mitotic Labeling Curve - MCA - Induced Rat Sarcoma Cells grown in vitro.
TABLE 1

$^3$HThdR Labeling Dose and Incorporated Radioactivity

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Dose</th>
<th>Pulse</th>
<th>DPM Per Nucleus $\times 10^{-3}$</th>
<th>Labeling Index (%)</th>
<th>DPM Per Labeled Nucleus</th>
<th>Rads/day Per gm Labeled Nuclear DNA</th>
<th>Rads/day Per gm Labeled Nucleus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>1.0 µCi/gm</td>
<td>4 hrs.</td>
<td>1.09</td>
<td>3.0</td>
<td>.036</td>
<td>374.4</td>
<td>$4.58 \times 10^{-9}$</td>
</tr>
<tr>
<td></td>
<td>2.0 µCi/gm</td>
<td>4 hrs.</td>
<td>2.40</td>
<td>3.1</td>
<td>.077</td>
<td>806.4</td>
<td>$9.87 \times 10^{-9}$</td>
</tr>
<tr>
<td></td>
<td>10.0 µCi/gm</td>
<td>4 hrs.</td>
<td>15.50</td>
<td>6.7</td>
<td>.23</td>
<td>2,419.2</td>
<td>$2.96 \times 10^{-8}$</td>
</tr>
<tr>
<td>Spleen</td>
<td>1.0 µCi/gm</td>
<td>4 hrs.</td>
<td>4.2</td>
<td>46.7</td>
<td>.009</td>
<td>70.6</td>
<td>$1.17 \times 10^{-9}$</td>
</tr>
<tr>
<td></td>
<td>2.0 µCi/gm</td>
<td>4 hrs.</td>
<td>6.14</td>
<td>46.8</td>
<td>.013</td>
<td>100.8</td>
<td>$1.67 \times 10^{-9}$</td>
</tr>
<tr>
<td></td>
<td>1.0 µCi/gm</td>
<td>4 hrs.</td>
<td>42.8</td>
<td>44.5</td>
<td>.096</td>
<td>745.9</td>
<td>$1.24 \times 10^{-8}$</td>
</tr>
<tr>
<td>HeLaS3</td>
<td>0.01 µCi/ml</td>
<td>20 min.</td>
<td>$3.36 \times 10^{-4}$</td>
<td>30</td>
<td>$1.12 \times 10^{-3}$</td>
<td>6.29</td>
<td>$1.44 \times 10^{-10}$</td>
</tr>
<tr>
<td></td>
<td>0.10 µCi/ml</td>
<td>20 min.</td>
<td>$3.14 \times 10^{-3}$</td>
<td>30</td>
<td>$1.07 \times 10^{-2}$</td>
<td>60.04</td>
<td>$1.38 \times 10^{-9}$</td>
</tr>
<tr>
<td></td>
<td>1.0 µCi/ml</td>
<td>20 min.</td>
<td>$2.58 \times 10^{-2}$</td>
<td>30</td>
<td>$8.6 \times 10^{-2}$</td>
<td>482.4</td>
<td>$1.11 \times 10^{-8}$</td>
</tr>
<tr>
<td></td>
<td>2.0 µCi/ml</td>
<td>20 min.</td>
<td>$6.41 \times 10^{-2}$</td>
<td>30</td>
<td>$2.14 \times 10^{-1}$</td>
<td>1202.4</td>
<td>$2.76 \times 10^{-8}$</td>
</tr>
<tr>
<td></td>
<td>10.0 µCi/ml</td>
<td>20 min.</td>
<td>$3.44 \times 10^{-1}$</td>
<td>30</td>
<td>1.15</td>
<td>6465.6</td>
<td>$1.49 \times 10^{-7}$</td>
</tr>
</tbody>
</table>
Fig. 1

**LIVER**

![Graph showing the percent metaphase labeling over time after 3HTdR.](image)

**Spleen**

![Graph showing the percent metaphase labeling over time after 3HTdR.](image)

Reproducibility of the original page is poor.
Fig. 2

% Labeled Mitoses

HOURS

0 10 20 30 40 50
Fig. 5

% LABELED MITOSES

HOURS
Fig. 6

% LABELED MITOSES vs. HOURS
**Fig. 7: Control Rats - No Radiation**

- Mean
- I-Range

**Fig. 8: Rats Treated with $^3$HdR (10 $\mu$Ci/gm.)**

Dilution Titre vs Days after SRBC.
Fig. 9

% LABELED MITOSES

0 10 20 30 40 50
0 10 20 30 40 50

HOURS